SCHEMBL4492706

SCHEMBL4492706

COc1ccc2cc(C(=O)O)c(NCc3ccccc3Cl)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.47
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 4/20 0.44
MAPK1 P28482 2/20 0.44
MAPT P10636 5/20 0.43
LMNA P02545 4/20 0.43
TP53 P04637 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.43
HTT P42858 1/20 0.43
MAPK8 P45983 1/20 0.43
HPGDS O60760 1/20 0.43
HPGD P15428 2/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.42
PLA2G1B P04054 1/20 0.42
KMT2A Q03164 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
GFER P55789 1/20 0.42
FABP3 P05413 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482389 0.90 CDK2 (0.43) CSNK1DALDH1A1KDM4EMAPTLMNA
SCHEMBL4489260 0.85 HPGDS (0.55) ALDH1A1KDM4EMAPK1MAPTLMNA
SCHEMBL4490500 0.83 CTNNB1 (0.51) KDM4EMAPTLMNAHTTHPGDS
SCHEMBL4501469 0.82 APEX1 (0.49) CSNK1DMAPK1LMNASMN1; SMN2HTT
SCHEMBL4487073 0.82 KDM4E (0.53) ALDH1A1KDM4EMAPTTP53HPGDS
SCHEMBL4490345 0.81 FABP3 (0.51) ALDH1A1KDM4EMAPTLMNATP53
SCHEMBL4500058 0.81 SMN1; SMN2 (0.53) ALDH1A1MAPK1MAPTLMNASMN1; SMN2
SCHEMBL4489494 0.81 HIF1A (0.60) ALDH1A1KDM4EMAPTLMNATP53
SCHEMBL4482218 0.80 ALDH1A1 (0.46) CSNK1DALDH1A1KDM4EMAPK1MAPT
SCHEMBL4487533 0.79 KDM4E (0.45) ALDH1A1KDM4EMAPTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 CSNK1D 430/4885ALDH1A1 3862/4885KDM4E 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.